Mark E. Labadia
Boehringer Ingelheim (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Immune Response and Inflammation, Protease and Inhibitor Mechanisms, Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction
Most-Cited Works
- → Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor(1990)746 cited
- → RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients(2018)309 cited
- → High-Affinity Interactions of Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) and CD40 Require TRAF Trimerization and CD40 Multimerization(1999)148 cited
- → Discovery and Characterization of a Substrate Selective p38α Inhibitor(2004)110 cited
- → Epstein‐Barr virus‐induced gene 3 negatively regulates IL‐17, IL‐22 and RORγt(2008)97 cited
- → Design and Synthesis of Dipeptide Nitriles as Reversible and Potent Cathepsin S Inhibitors(2002)83 cited
- → Molecular Regulation of the Interaction Between Leukocyte Function-Associated Antigen-1 and Soluble ICAM-1 by Divalent Metal Cations(1998)76 cited
- → Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors(2017)59 cited
- → Catalysis and Function of the p38α·MK2a Signaling Complex(2004)51 cited
- → An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients(2018)47 cited